CAS No. 1456803-39-6, (3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3- aminium 4-methylbenzoate

As an oral calcitonin gene-related peptide (CGRP) receptor antagonist, Ubrogepant offers fast-acting, effective relief for acute migraines without the typical adverse effects of triptans. This novel approach paves the way for a new era in migraine management, providing patients with a much-needed alternative. By incorporating Ubrogepant into your pharmaceutical portfolio, you can make a significant impact on improving the lives of migraine sufferers and advance neurological care.

At Unibest, we profoundly understand the diverse needs of the pharmaceutical industry, and to meet these needs, we have developed and included CAS RN 1456803-39-6 in our portfolio. This compound forms an important part of the synthesis process of Ubrogepant, expediting drug production for our pharmaceutical partners globally.

The compound CAS RN 1456803-39-6, essentially the 4-methylbenzoic acid form of the other half of the Ubrogepant building block, comprises Alanine derivatives as its starting materials. This intermediate bears a close resemblance to the earlier described Ubrogepant intermediate CAS RN 1456803-37-4, maintaining an integral role in Ubrogepant's synthetic process.